GSK delivered sales and earnings ahead of expectations, yet the shares suffered one of the FTSE 100's steepest falls on Wednesday as investors focused on vaccines and the cost of building the pipeline.

Beating forecasts is usually a reliable way for a company to please the market. Wednesday 28 October 2026 showed that it is not always enough. GSK (LSE:GSK) reported third-quarter sales and earnings that came in ahead of expectations, but its shares fell 4.78%, widely reported as 4.8%, to close at 1,831.50p.

The decline was one of the main reasons the FTSE 100 could manage only a modest gain on Budget day. The index rose 7.96 points to 10,694.50, as strength in banks was offset by losses in GSK and Unilever (LSE:ULVR). Market reports said that personal care, drug and grocery stocks fell nearly 1.4% as a group, and described the two consumer and healthcare heavyweights as having results that failed to impress investors.

A beat with a weak spot

On the face of it, GSK's numbers were solid. Third-quarter turnover reached £8.9bn, up 5% at constant exchange rates (CER) and 4% at actual rates. Core earnings per share were 54.6p, up 1% at CER, while total earnings per share fell 21% at CER to 38.5p.

The distinction between core and total earnings is important. Core measures strip out certain items, such as some amortisation, restructuring and other adjustments, to show what management considers the underlying performance. Total, or reported, earnings include those items. A large gap between the two often reflects one-off or non-cash charges, and investors usually look at both.

The weak spot was vaccines. According to reports, vaccines contributed less than consensus expectations. The division's sales came in at £2.6bn, down 2% at CER, and within that Shingrix generated £0.8bn, down 5% at CER. When one of a group's major businesses falls short of what analysts had pencilled in, a headline beat elsewhere may not be enough to offset the disappointment.

By contrast, Specialty Medicines grew sharply, with sales of £3.9bn, up 15% at CER. General Medicines was broadly stable at £2.4bn.

Pipeline ambitions and investor patience

The second strand of the reaction concerned GSK's push to build its pipeline. Reports said investors were not persuaded by that effort, at least on Wednesday's evidence.

GSK pointed to a busy period of regulatory progress. Hibsago was approved in the US and Japan for chronic hepatitis B. Jemperli gained US approval for locally advanced dMMR/MSI-H rectal cancer, and Jideytro was approved in the US for second-line ROS1-positive non-small cell lung cancer. The company also started a phase III trial of an mRNA seasonal flu vaccine and said it had made 18 of the 22 phase III starts planned for 2026.

Pipeline investment is a long game. Late-stage trials are costly and can take years to read out, while the revenue they may eventually generate is uncertain. Markets often weigh the near-term cost of that activity against the potential longer-term reward, and on this occasion the balance appears to have tilted toward caution. For a company in GSK's position, each approval and each trial start adds to the evidence investors will use to judge whether the spending is justified, but that judgement tends to form over several quarters rather than on a single results day. Patience, in other words, was in short supply on Wednesday.

Alongside the pipeline, GSK is running its Accelerate Growth programme, which targets £1.9bn of annual savings by 2029, at an expected total cost of £2.4bn. Restructuring costs of this kind are one reason total and core earnings can diverge.

Chief executive Luke Miels said GSK had delivered another good quarter.

GSK reaffirmed its 2026 guidance at constant exchange rates. It expects turnover growth of 3–5%, toward the upper half of that range; core operating profit growth of 7–9%, also in the upper half; and core earnings per share growth of 7–9%, in the lower half.

The company also noted that the £2bn buyback announced in FY2024 had been completed in the second quarter of 2026, and no new buyback was announced. The third-quarter dividend was set at 17p, with 70p expected for the full year.

Reaffirmed guidance with no upgrade can sometimes leave a share price exposed when expectations have risen. Before the results, GSK shares had gained 27% over two years.

A sector under pressure

GSK's fall formed part of a broader pull on defensive names. Unilever fell 2.05% to 4,792p after its own trading update, with market reports citing softer results in foods.

That weakness contrasted with the banks, which gained 1.1% as a sector after the Budget's bank surcharge rose to 6% rather than the 8% some investors had feared. The divergence helps explain why the FTSE 100 barely moved overall: gains in one large sector were offset by losses in another.

Pharma will remain in focus through the week. AstraZeneca (LSE:AZN), valued at about £196bn, reports third-quarter results on Friday 30 October, while Haleon (LSE:HLN) issues a trading statement on Thursday.

Key dates to watch

  • Thu 29 Oct 2026: Haleon's Q3 trading statement adds another healthcare-related read-across.
  • Fri 30 Oct 2026: AstraZeneca reports Q3 results, offering a comparison point for GSK within FTSE 100 pharma.
  • Thu 5 Nov 2026: The Bank of England's MPC decision and Monetary Policy Report, relevant to the whole index.
  • Wed 2 Dec 2026: The FTSE December review announcement after the close, based on 1 December market caps.

The bottom line

GSK's 4.8% fall demonstrates that beating forecasts is not the same as satisfying investors. A softer vaccines contribution, led by a 5% decline in Shingrix sales, and doubts about the payoff from heavy pipeline investment outweighed Specialty Medicines growth and reaffirmed guidance. The company's pipeline approvals and savings programme give it material to point to over time, but on Wednesday the market focused on where the quarter fell short. Friday's AstraZeneca results will show whether that cautious mood extends across the sector.